$LLLI: Lamperd Less Lethal Receives Follow-Up Orders from

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams
149
$LLLI: Lamperd Less Lethal Receives Follow-Up Orders from Talion Defense Corp. for Components of Advanced Riot Control Munitions to be Manufactured in the USA

Talion Performing Assembly and Arming of Lamperd Designed Products for Marketing to US Police and Corrections Agencies


Link: https://www.otcmarkets.com/filing/html?id=154...FniGBAxOth

SARNIA, ON / December 21, 2021 / Lamperd Less Lethal, Inc. (OTC PINK: LLLI), an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies worldwide, has received follow-up orders from its new Colorado based manufacturer and sales distributor, Talion Defense Corp. (https://www.taliondefense.com).

As with Talion’s initial order in November, Lamperd will supply components of its advanced riot control munitions intended for US police and corrections agencies with which Talion has established relationships. Since Talion imports only inert components of the Lamperd products into the US, this arrangement greatly reduces regulatory issues. Talion performs assembly and arming these components at its own facility to be sold as finished Talion Defense Corp. products. These products can therefore be labeled as “Made in Colorado, USA” making them more appropriate for US buyers.

Oliver Mazurkiewicz, Talion's Agency Sales Lead noted: "We are seeing a great deal of excitement for these less lethal products in the US market and are going to be holding a series of multi-agency demos in January of 2022. We believe the Lamperd products bring a proven quality option to what is certainly a significant agency need."

Barry Lamperd, CEO of Lamperd Less Lethal stated, “We are very impressed by the diligent efforts of our new business associates at Talion to quicky set up their manufacturing and sales operation for Lamperd designed security products in the vast US marketplace. With all the crisis situations happening in the US today, and the demands to find more effective less lethal response products, we foresee a major opportunity for sales growth. Talion is giving us just the presence to grow our market share in the USA at this time when it is needed most. Lamperd products have been extensively developed and tested to be the most effective and also the safest in the less lethal industry so they can be of great help in maintaining order and helping to save more lives.”

For information on purchasing these US-made products, please contact the Agency Sales Team of Talion Defense at info@taliondefense.com or (970) 344-5667.

About Lamperd Less Lethal:

Lamperd Less Lethal, Inc. (LLLI) is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 37mm & 40mm launching systems and interlocking riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors.


For more information visit: http://www.lamperdlesslethal.com.


This press release contains forward-looking statements relating to Lamperd Less Lethal, Inc. Lamperd Less Lethal, Inc. undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results.Safe Harbor for Forward-Looking Statements:This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact: Lamperd Less Lethal, Inc.

Barry Lamperd, President & CEO

(519) 344-4445

Email: info@lamperdlesslethal.com or sales@lamperdlesslethal.com

Company Website: http://www.lamperdlesslethal.com

Lamperd Less Lethal on Facebook: https://www.facebook.com/lamperdlesslethal


Lamperd Less Lethal on Instagram: https://www.instagram.com/llli_lamperd_lesslethal

Lamperd Less Lethal on Twitter: https://www.twitter.com/LLLI_LessLethal

Barry Lamperd on Twitter: https://www.twitter.com/lamperd_llli
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 170

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 358

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 336

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 364

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 86

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 372

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 64

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Trump's Executive Orders and Their Economic Impact

Updated Category News Views 806

Executive Orders: A Shift in Economic Paradigms President Trump has taken significant steps by issuing a number of executive orders that have raised eyebrows among economists and market analysts alike. According to market expert Louis Navellier, this approach can be characterized as 'shock and awe'. It reflects a bold strategy that could reshape various aspects of the...

Continue Reading
B2PRIME Expands Institutional Reach with Stuart Brock's Addition

Updated Category News Views 173

B2PRIME Welcomes Stuart Brock as Institutional Business Development Manager B2PRIME Group, a leading financial services provider for institutional and professional clients, recently announced the appointment of Stuart Brock as its Institutional Business Development Manager. With over 15 years of experience in electronic trading and institutional sales, Stuart is poised to...

Continue Reading
United Parks & Resorts Inc. Shares Q1 2025 Financial Insights

Updated Category News Views 374

Financial Overview of United Parks & Resorts Inc. United Parks & Resorts Inc. (NYSE: PRKS), a prominent player in the theme park and entertainment sector, has recently shared its financial results for the first quarter of 2025. This report delves into the key metrics and operational insights that define the company’s performance in this period. Attendance and Revenue...

Continue Reading
Seongnam Pavilion Sets New Benchmark at CES 2025 with 41 Companies

Updated Category News Views 178

Seongnam Pavilion Makes Waves at CES 2025 At the latest CES 2025, Seongnam City showcased an impressive turnout at the world's leading consumer electronics exhibition. This year, Seongnam participated with a remarkable delegation of 41 companies, marking the largest participation ever. Focused on enhancing their global footprint, these small and medium-sized enterprises...

Continue Reading
Gaucho Holdings Seizes Opportunities Amid Argentina's Economic Revival

Updated Category News Views 179

Gaucho Holdings and the New Economic Landscape in Argentina Recently, Argentina has entered a new chapter of economic transformation. A shift in leadership, with Javier Milei becoming president, has sparked hopes for fiscal discipline, growth, and development. As the country embraces pro-market reforms, Gaucho Group Holdings, Inc. (NASDAQ: VINO) positions itself to...

Continue Reading